African trypanosomes, genus Trypanosoma, are protozoan parasites that cause widespread disease in livestock and humans. Africa is currently experiencing a resurgence in the incidence of both forms of this disease, and in some areas the mortality related to human African trypanosomiasis is estimated to be the same as that caused by AIDS (3) . The reemergence of African trypanosomiasis as a public health and agricultural threat has prompted renewed interest in the identification of novel virulence factors to expand the understanding of the pathogenesis of this group of diseases and to facilitate drug and vaccine development.
Peptidases are widely implicated as virulence factors and chemotherapeutic targets in parasitic diseases (13) . Although peptidase activities in the plasma of Trypanosoma brucei brucei-infected rodents have been reported (5, 11) , and the extracellular release of cysteine peptidase by T. b. brucei in vitro has been demonstrated (1, 12) , no parasite-derived peptidase that is released into the host has ever been identified. We report here the identification of the enzyme responsible for up to 80% of the trypsin-like hydrolytic activity observed in the plasma of rats infected with T. b. brucei. Based on partial amino acid sequencing and kinetic and immunochemical characterization of the peptidase, we have identified it as T. b. brucei oligopeptidase B (OP-Tb) (the opdB gene product [8] ).
A serine oligopeptidase activity is present in T. b. bruceiinfected rat plasma. Adult male Sprague-Dawley rats (n ϭ 3)
were infected intraperitoneally with T. b. brucei ILTat1.1 (10 6 trypanosomes per rat). At peak bloodstream parasitemia (ϳ3 ϫ 10 8 trypanosomes ⅐ ml Ϫ1 ), rats were euthanatized by ether asphyxiation. Blood was harvested by cardiac puncture, diluted 1:1 with 57 mM Na 2 HPO 4 -3 mM NaH 2 PO 4 -44 mM NaCl-56 mM D-(ϩ)-glucose-0.1 mM hypoxanthine-2% (m/ vol) sodium citrate, pH 7.4 (PSGT), and centrifuged (1,500 ϫ g, 5 min, 25°C), and supernatants were confirmed to be trypanosome free by light microscopy. An N ␣ -carbobenzyloxy-Larginyl-L-arginyl-7-amido-4-methylcoumarin (Cbz-Arg-Arg-AMC)-hydrolyzing activity that was minimal in healthy, uninfected rats was detected in the plasma of infected rats (Table 1) . This activity was sensitive to the low-molecular-mass serine peptidase inhibitors 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) and 3,4-dichloroisocoumarin and insensitive to the cysteine peptidase inhibitor E-64, implicating a serine peptidase. This activity was also insensitive to the high-molecular-mass serine peptidase inhibitors soybean trypsin inhibitor and turkey ovomucoid, suggesting that the enzyme was an oligopeptidase. Purified trypanosomes subjected to the same centrifugation steps in a variety of media did not liberate CbzArg-Arg-AMC-hydrolyzing activity, nor did they liberate acetylesterase or acid phosphatase activity, two intracellular markers (15) which would be expected if trypanosomes were damaged during the process (results not shown). This suggests that the processing of the plasma did not cause artifactual release of peptidase activity from the trypanosomes. The kinetic profile of the activity identified in T. b. brucei-infected rat plasma (Table 1) was not unlike that of a trypanosome serine oligopeptidase (OP-Tb) that has been cloned and characterized from T. b. brucei (8) . Since chicken egg yolk (IgY) antibodies to OP-Tb were available, we then probed infected rat plasma for OP-Tb by Western blotting.
Anti-OP-Tb antibodies cross-react with an 80-kDa protein in T. b. brucei-infected rat plasma on a Western blot. Plasma was partially fractionated by three-phase partitioning (TPP) by dilution to 100 ml with 0.1% (m/vol) Brij 35 and addition of t-butanol (44 ml) to 30% (vol/vol) in 144 ml. Solid (NH 4 ) 2 SO 4 (14.4 g) was added and the suspension was centrifuged (10,000 ϫ g, 10 min, 25°C) to yield a 0 to 10% (NH 4 ) 2 SO 4 TPP fraction. The interfacial pellet was discarded, and a 10 to 25% (NH 4 ) 2 SO 4 TPP fraction was prepared by adding solid (NH 4 ) 2 SO 4 (21.6 g) to the aqueous phase-organic phase mixture and recentrifuging. The 10 to 25% (NH 4 ) 2 SO 4 TPP fraction was resuspended in 50 mM Tris-HCl-1 mM dithiothreitol (DTT), pH 8 (buffer A; 40 ml), and applied to a para-aminobenzamidine-Sepharose column (120 by 15 mm, 1 ml ⅐ min Ϫ1 ) equilibrated in buffer A. Bound protein, eluted with 250 mM NaCl in buffer A, was resolved by Tris-Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and probed for immunoreactive OP-Tb by Western blotting with anti-OP-Tb IgY as described in reference 7. Fractionated plasma from T. b. brucei-infected rats yielded a single strong band on a Western blot (Fig. 1A, lanes b and c) , whereas no band was evident in similarly treated plasma from a healthy rat (Fig. 1A, lane a) . These bands correspond to those seen for purified OP-Tb (Fig. 1A,  lane d) . These data illustrate that immunoreactive OP-Tb is present in the plasma of T. b. brucei-infected rats and not in the plasma of uninfected rats. We now attempted to address whether the OP-Tb we had detected by Western blotting in infected rat plasma was responsible for the Cbz-Arg-Arg-AMC-hydrolytic activity.
Anti-OP-Tb antibodies neutralize Cbz-Arg-Arg-AMC-hydrolytic activity in T. b. brucei-infected rat plasma. Although we detected OP-Tb in T. b. brucei-infected rat plasma by Western blotting, it was not known whether the OP-Tb was catalytically active and thus responsible for the observed Cbz-ArgArg-AMC-hydrolytic activity. Several host-derived plasma peptidases (including members of the coagulation and complement systems) can also hydrolyze Cbz-Arg-Arg-AMC, as can mast cell tryptase, which would probably be produced during the inflammatory response to an infection. We thus required a tool that could selectively neutralize OP-Tb activity in whole plasma. Since polyclonal antibodies to enzymes can abrogate enzyme activity, we evaluated IgY fractions, obtained over the OP-Tb immunization protocol described in reference 7, for their ability to inhibit the activity of OP-Tb (25 ng ⅐ ml Ϫ1 , purified as described in reference 8) against 5 M Cbz-ArgArg-AMC in 50 mM Tris-HCl, pH 8. IgY preparations inhibited OP-Tb activity against Cbz-Arg-Arg-AMC to various degrees ( Fig. 2A, inset ). Week 13 IgY produced 92% inhibition of OP-Tb activity at 250 g ⅐ ml Ϫ1 , and the inhibitory activity of week 13 IgY was titrated out with half-maximal inhibition at 7.5 g ⅐ ml Ϫ1 ( Fig. 2A ). This represents some of the most potent activity-neutralizing antibodies described to date. Week 13 anti-OP-Tb IgY had no effect (at 250 g ⅐ ml Ϫ1 ) on the hydrolytic activity of several mammalian serine peptidases, including neutrophil elastase, plasmin, thrombin, factor Xa, plasma kallikrein, trypsin, chymotrypsin, and mast cell tryptase (results not shown). The selective inhibition of OP-Tb by these antibodies provided us with a tool with which to characterize the potential OP-Tb activity in T. b. brucei-infected rat plasma.
Rats (n ϭ 3) were infected as described above. Blood (ϳ125 l) was drawn daily from the tail vein into an equal volume of PSGT and centrifuged (1,500 ϫ g, 5 min, 25°C). Hydrolytic activity against Cbz-Arg-Arg-AMC was observed in trypanosome-free plasma of infected rats on day 4, at ϳ4 ϫ 10 6 trypanosomes ⅐ ml Ϫ1 (Fig. 2B ), followed by a steady increase in parasitemia and plasma Cbz-Arg-Arg-AMC-hydrolyzing activity. Activity was completely inhibited by 1 mM AEBSF (results not shown) and was abolished by up to 80% in the presence of anti-OP-Tb IgY (250 g ⅐ ml Ϫ1 ) relative to activity determined in the presence of preimmune IgY at the same concentration (Fig. 2B ). These data illustrate that the bulk of the Cbz-ArgArg-AMC hydrolytic activity in T. b. brucei-infected rat plasma is most likely attributable to trypanosome-derived OP-Tb. To unequivocally identify the responsible peptidase, we then sought to purify the Cbz-Arg-Arg-AMC-hydrolyzing factor from T. b. brucei-infected rat plasma. 
a Inhibitor concentrations reflect the concentrations required for maximum inhibition of Cbz-Arg-Arg-AMC-hydrolytic activity in the sample. Increasing the inhibitor concentrations by up to double those reported here did not increase the degree of inhibition observed.
b Trypanosome-free plasma from acutely infected rats and plasma from healthy rats was assayed for activity against Cbz-Arg-Arg-AMC (5 M) in 50 mM Tris-HCl-1 mM DTT, pH 8, at 37°C. Purification and sequencing of the peptidase from the plasma of T. b. brucei-infected rats. The peptidase was purified 16,336-fold from parasite-free T. b. brucei-infected rat plasma, with a 34% yield ( Table 2) . Plasma (47 ml) from six rats was diluted to 100 ml with 0.1% (m/vol) Brij 35, and a 10 to 25% (NH 4 ) 2 SO 4 TPP fraction was prepared as described above. The fraction was resuspended in 30 mM NaH 2 PO 4 -1 mM DTT, pH 6.8 (30 ml), and dialyzed against the same buffer (2 ϫ 4,000 ml, 16 h, 4°C). During dialysis, some protein precipitated. This was removed by centrifugation (15,000 ϫ g, 30 min, 4°C), and the resultant supernatant (46 ml) was loaded onto a Cibacron blue F3GA-Sepharose column (200 by 25 mm, 0.8 ml ⅐ min Ϫ1 ) equilibrated in 30 mM NaH 2 PO 4 , pH 6.8. The Cibacron blue F3GA-Sepharose flowthrough fraction, containing all the Cbz-Arg-Arg-AMC-hydrolyzing activity, was dialyzed against 50 mM Tris-HCl-100 mM NaCl-1 mM DTT (buffer B; 2,000 ml, 4 h, 4°C) and applied to a Q-Sepharose column (26 by 100 mm, 1 ml ⅐ min Ϫ1 ) equilibrated in buffer B. Bound material was eluted with a linear gradient of 0.1 to 1 M NaCl in buffer B, over five column volumes (Fig. 3A) . Eluted fractions displaying activity against Cbz-Arg-Arg-AMC were pooled, dialyzed (2,000 ml, 4 h, 4°C) against buffer A, and loaded onto a para-aminobenzamidine-Sepharose column (120 by 15 mm, 1 ml ⅐ min Ϫ1 ) equilibrated in buffer A. Bound protein was eluted in a single step with 250 mM NaCl in buffer A (Fig. 3B) . The active fraction from para-aminobenzamidine-Sepharose (44 ml) was made to 1 M (NH 4 ) 2 SO 4 and loaded onto a phenylSepharose column (100 by 25 mm, 1 ml ⅐ min Ϫ1 ) equilibrated in 1 M (NH 4 ) 2 SO 4 in buffer A. Bound protein was eluted with a linear gradient of 1.0 to 0 M (NH 4 ) 2 SO 4 in buffer A over 10 column volumes (Fig. 3C) , and the eluted active fractions were pooled (30 ml). The sample was dialyzed against buffer B (2,000 ml, 4 h, 4°C) and applied to a poly-L-lysine-Sepharose column (90 by 15 mm, 1 ml ⅐ min Ϫ1 ) equilibrated in buffer B. Bound protein was eluted with a linear gradient of 0.1 to 1.0 M NaCl in buffer B (Fig. 3D) . The active fractions eluted from poly-L-lysine-Sepharose were pooled (20 ml), concentrated by ultrafiltration in polysulfone concentrators to 2 ml, and applied to a Sephacryl S-100 HR column (900 by 15 mm, 0.32 ml ⅐ min Ϫ1 ) equilibrated in buffer A (Fig. 3E) . The pooled active fractions yielded a single 80-kDa band by reducing TrisTricine-SDS-PAGE (Fig. 1B, lane b) . Two peptides yielded by endoproteinase Lys-C digests of the purified protein were purified by high-pressure liquid chromatography, and subjected to N-terminal sequence analysis. The sequences of these two peptides, TPGEGEDEEIVLD and MDLESGHFSASDR, match exactly residues 124 to 136 and 677 to 689, respectively, of the deduced amino acid sequence of the T. b. brucei opdB gene (8) .
Why does OP-Tb remain catalytically active in the host bloodstream, despite an abundance of serine peptidase inhibitors? It has previously been shown that OP-Tb isolated directly from trypanosomes was not inhibited by mammalian plasma serpins (17) . OP-Tb activity is therefore unregulated after release into the bloodstream. Furthermore, OP-Tb neither binds to nor is inhibited by ␣ 2 -macroglobulin (17) , and therefore it is not subject to the same clearance mechanisms as other peptidases when released into the blood (4). OP-Tb would thus be cleared more slowly from the host bloodstream than would other exogenous peptidases, and this may account for its persistence in the host circulation.
T. b. brucei does not release OP-Tb activity in vitro.
How does OP-Tb get out of the trypanosomes and into the host bloodstream? To address this question, we incubated trypomastigote-form T. b. brucei (10 8 cells ⅐ ml Ϫ1 , 37°C) as described in reference 9. Aliquots (1 ml) were removed at 30-min intervals for 4 h and centrifuged (1, 500 ϫ g, 2 min, 25°C) . No Cbz-Arg-Arg-AMC-hydrolyzing activity was identified in cellfree culture supernatants. However, Cbz-Arg-Arg-AMC-hydrolyzing activity was detected in the Triton X-100-solubilized pellet fraction from the same cultures (results not shown). These results indicate that there was no observable release of OP-Tb by live trypanosomes over the time frame of the experiments. This is consistent with observations that the deduced amino acid sequence of the opdB gene does not contain any known secretion sequences (8) and that the OP-Tb homologue in Trypanosoma cruzi appears, by electron microscopy, to be cytosolic (2) . It seems most likely that OP-Tb is released in vivo by dead or dying trypanosomes that are lysed in the host circulation by the various antimicrobial host defense mechanisms (e.g., the alternative pathway of complement activation).
OP-Tb retains full catalytic activity after release into the host plasma. Kinetic analysis of OP-Tb isolated from infected rat plasma was undertaken as described in reference 8. (8) . Thus, after release into the host plasma, neither the substrate specificity (as reflected by the K m ) nor the catalytic power (as reflected by the k cat ) of OP-Tb was altered. OP-Tb released into the host plasma had a pH optimum of 9 and remained 75% active at physiological pH, compared to activity at pH 9 (results not shown). Furthermore, it has been shown that OP-Tb isolated from trypanosomes is maximally stable at pH 7.5 (8) , indicating that the host bloodstream is an ideal catalytic environment for OP-Tb.
Implications of the extracellular release of OP-Tb. We illustrate here that OP-Tb is released by T. b. brucei into the plasma of infected rats, where it persists and retains full catalytic activity. One implication of a foreign, highly catalytic (k cat Ͼ 120 s Ϫ1 ) peptidase accumulating in the host plasma is that it is in an ideal position to influence the dynamics of biologically active peptides in the bloodstream. The anomalous degradation of peptide hormones in host tissues would seriously impair host metabolic homeostasis. The potential importance of this is underscored by the observed reduction in the levels of one peptide hormone, atrial natriuretic factor, in the plasma of T. b. brucei-infected dogs (10) . Atrial natriuretic factor is a substrate for OP-Tb in vitro (17) , but it is not known whether the observed depletion in the levels of this hormone in plasma are due to OP-Tb activity. Support for this idea is also lent by reports of the unusual cleavage of peptide hormones added exogenously to the serum of T. b. brucei-infected rats (16) , where investigators concluded that the activity was due to a trypanosome-derived serine peptidase. OP-Tb has similar properties; however, the activity reported in reference 16 was After processing by TPP and Cibacron blue F3GA-Sepharose chromatography, plasma was subjected to chromatography on Q-Sepharose at pH 8 (A), para-aminobenzamidine-Sepharose (B), phenyl-Sepharose (C), poly-L-lysine-Sepharose (D), and Sephacryl S-100 HR (E). -, A 280 ; s, activity against Cbz-Arg-Arg-AMC; . . . , salt gradient. Application of a step gradient is indicated by an arrow. partially inhibited by 3.5 mM EDTA and 5 mM ␣-DL-difluoromethylornithine. Since OP-Tb is not inhibited by EDTA (8) or ␣-DL-difluoromethylornithine (6) it is possible that the effects of multiple peptidases were being observed.
Indirect support for a role for OP-Tb in the pathology of trypanosomiasis comes from the recent report that administration of OP-Tb inhibitors improved the survival rate of mice infected with T. b. brucei (9) . However, there was no significant correlation between OP-Tb-inhibitory potency and in vitro antitrypanosomal efficacy of these inhibitors. Considering the data presented in this report, these inhibitors may have been acting on OP-Tb released into the plasma of the infected rodents, rather than on OP-Tb in the parasite cytosol, and, in doing so, they influenced the course of the infection.
This study represents the first report of the conclusive identification of any parasite-derived peptidase that is released into the host system, and as such, it lends critical support to the emergence of peptidases as important virulence factors and chemotherapeutic targets in trypanosome infections.
